Granted Patent B2

US 12,325,697 · App. 17/658,587 · Granted Jun 10, 2025

Inventors: Silvana Marcel Leit De Moradei (Burlington, MA); Angela V. West (Franklin, MA); Thomas Baker (Nottingham, GB); Jokin Carrillo Arregui (Nottingham, GB); Diana Castagna (Nottingham, GB); Jeremy Robert Greenwood (Brooklyn, NY); Salma Rafi (Lexington, MA); Fiona McRobb (New York, NY); Yan Zhang (Jersey City, NJ)

Assignee: Nimbus Clio, Inc.

C07D403/10A61P35/02C07D209/44C07D249/08C07D401/14C07D403/12C07D405/14C07D413/10C07D413/14C07D471/04C07D491/048C07D491/107C07D498/08C07D498/10C07F5/022

Abstract

Claims (20)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

Ring A together with its R 1 substituents is

Ring B together with its R 2 substituents is

Ring C together with its R 3 substituents is

each R 8 is independently hydrogen, fluoro, chloro, bromo, methyl, —CF 3 , —OH, or —OMe;

-L-R 9 is —COMe,

q is 0, 1, or 2; and

t is 0 or 1.

2. The compound of claim 1 , wherein Ring B together with its R 2 substituents is

3. The compound of claim 1 , wherein Ring B together with its R 2 substituents is

4. The compound of claim 1 , wherein the compound is either of the following formulae:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is any one of the following formulae:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is any one of the following formulae:

or a pharmaceutically acceptable salt thereof.

7. A compound selected from:

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

Assignments (16)

Continuity (3)

References Cited (100)